Objective:

To summarize the experimental rationale, clinical evidence, and emerging innovations in catheter-based normothermic intraperitoneal chemotherapy (CBIP) for gastric cancer with peritoneal metastasis (GCPM).

Approach:

Key Findings:

• Peritoneal metastasis occurs in 40-50% of stage IV gastric cancer patients and is associated with poor survival rates.
• Intraperitoneal chemotherapy allows for direct drug delivery, potentially overcoming limitations of systemic chemotherapy.
• CBIP has been adapted for GCPM and shows promise in clinical outcomes, though controlled trials are lacking.

Interpretation:

Limitations:

• Lack of controlled trials for CBIP in gastric cancer.
• Efficacy of HIPEC in GCPM remains questioned in recent studies.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.